Urinary N,N,N-tnmethylglycine (betaine) and N,N-dimethylglycine (DMG) have been identified and quantified for clinical purposes by proton nuclear magnetic resonance (1 H NMR) measurement in previous studies. We have assessed these procedures by using both one-dimensional (1-D) and 2-D NMR spectroscopy, together with pH titration of urinary extracts to help assign 'H NMR spectral peaks. The betaine calibration curve linearity was excellent (r = 0.997, P = 0.0001) over the concentration range 0.2-1.2mmoVL, and CVs for replicate betaine analyses ranged from 7% (n = 10) at the lowest concentration to 1% (n = 9) at the highest. The detection limit for betaine was <15 moVL. Urinary DMG concentrations were substantially lower than those of betame. Urinary betaine and DMG concentrations measured by 1H NMR spectroscopy from 13 patients with premature vascular disease and 17 normal controls provided clinically pertinent data. We conclude that 'H NMR provides unique advantages as a research tool for determination of urinary betaine and DMG concentrations.
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Indexing Terms: hyperhomocysteinemia/betaine:homocysteine methyltransferase/creatinine/dimethylglycine/inbom errors of metabolism
Since the early 1960s it has been recognized that inborn errors of amino acid metabolism that result in increased plasma homocysteine concentrations greatly enhance the risk of developing inappropriate intravascular coagulation and arteriosclerosis. These inborn errors include homozygous deficiency of the homocysteine catabolic enzymes and are collectively called homocystinuria.
In recent years, patients with premature vascular disease have been found to have a surprisingly high incidence of impaired methionine and homocysteine metabolism.
This impairment is often consistent with a heterozygous deficiency of cystathionine -synthase (Cf3S; EC 4.2. 1-, 2-D, one-, two-dimensional; BHMT, betaine:homocysteine methyltransferase; CI3S, cystathionine /3-synthase; COSY, correlation spectroscopy; COSYLR, long-range COSY; DMG, N,N-dimethylglycine; DSS, 3-(trimethylsilyl)-1-propanesulfonic acid; FHMT, P-methyltetrahydrofolate:homocysthine methyltransferase; LB, line broadening; NMR, nuclear magnetic resonance; and TSP, 3-(trimethylsilyl)propionic acid. Received November 15, 1993; accepted October 7, 1994.
Attempts have been made previously
to identify enzyme deficiencies among patients with premature vascular disease (including coronary artery disease, stroke, and peripheral vascular disease) who also had impaired methionine/homocysteine metabolism (1) (2) (3) (4) . The reaction pathways of the three primary enzymes involved in the catabolism of homocysteine are shown in Fig. 1 . The enzyme CS catalyzes the condensation of homocysteine with serine to produce cystathionine; deficiencies of this enzyme are responsible for most cases of homocystinuria (5) . The other two enzymes, N5-methyltetrahydrofolate:homocysteine methyltransferase (FHMT; EC 2.1.1.13) and betaine:homocysteine methyltransferase (BHMT; EC 2.1.1.5), remethylate homocyteine to methionine (5).
Concentrations
of CI3S and FHMT in humans can be assayed readily because these enzymes are expressed in skin fibroblasts and peripheral blood lymphocytes. However, BHMT, while active in the liver and kidney, is not known to be expressed in more accessible human tissues. In seeking deficiencies of BHMT in patients who have both premature vascular disease and impaired homocysteine metabolism, our working hypothesis has been that deficiency of the enzyme may result in an increase in betaine6 and a lowering of dimethylglycine (DMG) concentrations in plasma and urine. Thus, assessment of blood or urinary concentrations of these compounds may be of clinical value. However, measurement of betaine and DMG in these fluids is not straightforward by current standard chemical methods (6) (7) (8) . In a quest for a simple, convenient, sensitive, and reliable method, we explored and then demonstrated the feasibility of measuring urinary betaine and DMG in patients and controls by 'H nuclear magnetic resonance (NMR) spectroscopy.
'H NMR has been used to detect a wide range of metabolites, such as hippurate, lactate, and creatinine, in body fluids and living cells (9) (10) (11) . 'H NMR spectra of biofluids such as urine can be extremely informative, yielding "fingerprints" of the metabolic state of the body; the simplicity of sample collection and preparation for analysis is a particular advantage of the method. Analyses of such compounds often require only -0.5 mL of urine and typically take only a few minutes for a one-dimensional (1-D) NMR spectrum of 5X concentrated urine redissolved in D2O. However, spectral analysis can be complicated, and pattern recognition methods or other advanced data analysis techniques may be required. A similar technique has been useful 6 1-Carboxy-N,N,N-trimethyl methanaminium hydroxide, inner salt (CAS no. 107-43-7), or glycine betaine. for diagnosis, for investigating the pharmacokinetics of drugs (12) , and for classifring toxicological data by pattern recognition (6) . The concentrations of betaine and DMG in the urine of neonates are high, and therefore relatively straightforward to assay. In contrast, concentrations in urine from normal adults are low. The aim of the work presented here was to develop and evaluate an NMR method to compare low betaine and DMG concentrations in urine samples from adult control subjects and from patients who had both premature vascular disease and impaired homocysteine metabolism. We aimed to test the hypothesis that the impaired homocysteine metabolism in some of these patients might reflect subnormal BHMT activity. were used for all spectra (Wilmad Glass Co., Buena, NJ).
Materials and Methods

Patients and Control Subjects
Thirteen adult patients who had recently experienced a clinically confirmed vascular occlusion and who had been shown by an oral methionine loading test to have impaired methionine/homocysteine metabolism were selected. We also selected nine healthy adult controls (C1-C9), each of whom was age-and sex-matched with a different patient. Clinical and biochemical details are set out elsewhere (4) . In addition, we obtained samples from seven athletic young men (controls ClO-C 16). The procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 1983.
Sample Preparation
Urine samples (24-h) were collected and preserved with boric acid (10 g124-h sample). An extra sample was obtained from one control subject, after betaine ingestion at normal pharmacological concentrations (3 g twice daily for 1 week). Two 10.0-mL portions of each urine sample were freeze-dried and stored at -70#{176}C. The freeze-dried samples were dissolved in 2. (15) . The urine samples from the athletic young men, collected at a later date, were prepared in the same manner, except that the pH* was adjusted to 5.05 ± 0.05.
Urine from a control subject was also obtained to determine possible detection errors. This latter sample was freeze-dried in fractions of 20.0 mL, each of which was redissolved in 4.0 mL of D20 (1 h, room temperature). The samples were then pooled and centrifuged (10 mm, -600g). To 24.75 mL of this sample 247.5 L of DSS stock solution was added.
The PH* was adjusted to 5.1 with concentrated DC1 and NaOD. The sample was then divided into 45 separate fractions, to which various amounts of a stock solution of betaine were added (to give eight different concentrations).
The concentration of betaine in the stock solution was calibrated against DSS (with 'H NMR).
NMR Measurements
1-D NMR.
111 NMR spectra of the samples were obtained on a Bruker (Karlsruhe, Peak numberscorrespond to labels in Fig. 2 ; 6, chemical shift at pH 6.2; pK', experimentally determined pK in 020 at 25C; 8,,, limiting acid shift; 8.,, limiting base shift actually at neutral p0; pK,,", plc values at 25'C (in H20) + 0.52 (to convert to D20 solution); 6**, referencechemical shifts at pH 7.2 and 25'C (18); n.i., not-Identified N-methyl peak (20) .
Resonance multiplicity for each peak was singlet; group refers to groups of equivalent spins.
Exchanging with D20.
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was determined by varying the interpulse delay between 1 s and 60s. The 'H nuclei of betaine, creatinine, and DSS in genuine urine samples were found to be virtually fully relaxed when a 10-s interpulse delay was used.) A pulse length of 9 s corresponded to a 90#{176} "ifip angle. The DMG concentration was relatively low in all samples (except in the sample from the subject who had ingested betaine). Therefore, the free-induction decays were multiplied by a sine-bell apodization function for resolution enhancement. This procedure was justified by the observation that the line-widths of betame, creatinine, glycine, DMG, and DSS were all of the same order (-2-2.5
Hz), which meant that the effects of the sine-apodization on the integrals were essentially the same for all the resonances of interest. The glycine concentration data were obtained in the same manner.
2-D NMR.
A standard double-quantum filtered phase-sensitive correlation spectroscopy (COSY) experiment (time-proportional phase increments) was acquired to reveal the scalar couplings in one sample. 2-D long-range COSY (COSYLR) NMR (9O#{176}-t,---i--9O#{176}-r-t2) spectra (processed in the magnitude mode to avoid peak cancellations) (17) were obtained by using a delay (T) of 200 ms both at 400 MHz and 600 MHz. Phasesensitive 2-D homonuclear Hartmann-Hahn experiment spectra were also acquired by using a 200-ms spinlock time. Typically 512 spectra of 1K each were acquired for all 2-D spectra. Both dimensions were zero-filled to 2K and a shifted (0 = 90#{176}) sine-bell window was used for resolution enhancement in both dimensions.
Assignments.
Peaks in the 'H NMR spectra were identified by comparison (Table 1) with literature values of the chemical shifts (after correction of TSP shifts to DSS values) and coupling pattern (e.g., 10, [18] [19] [20] [21] , with the NMR spectra of authentic standard compounds, and by adding a small amount of authentic compound (22) to the sample, followed by the acquisition of an additional spectrum.
Betaine, for example, was added to 5 of the patients' samples and to 15 of the controls' samples.
pH titration and determination of apparent pKa values were used for further identification of the resonances.
The errors resulting from the integration of the spectra (including those from baseline corrections) depended on the LB factor used. They were estimated by reintegration of the DSS resonance in a typical spectrum with an LB of0.3, 3, or6 Hz. The CV(n = 10) for the integral was 1.4% for LB = 0.3 Hz, 2.6% for 3 Hz (average integral 94.7%), and 4.1% for 6 Hz (average integral = 94.1%). Consequently, LB = 0.3 Hz was chosen as being the optimal value. The additional CV associated with the phasing procedure was determined to be 0.6% (n = 6). Thus, the CV associated with the standard data treatment was on the order of 2%, cor- responding to an error of 4 mo1/L at the average betaine concentration.
Calculations
The pK values (in D20) were determined from a pH titration between pH* 0.9 and 7.5 of a urine sample from a patient. The pKa and limiting shifts for the acid and base forms, respectively, were determined by using the following equation:
where 6 is the chemical shift, 6, and 6, are the limiting acid and base chemical shifts, and ptC is the dissociation constant. pKa, 6,,, and 6., were determined from the experimentally obtained relation between 6 and pH by nonlinear fitting with a simplex routine written in Pascal for a MacIntosh llfx computer (adapted from ref.
23).
In correcting apparent pKa values (from pH* to pD), experimental values were first corrected by applying the equation: pD = pH5 + 0.44 (14) . This equation takes note of the fact that the pH electrode gives a reading, pH5, that is lower than pD. Second, since the degree of acid dissociation is less in D20 than in H20, we applied the correction pK(D20) = pK(H20) + 0.52 (24) . These approximate corrections were applied to the pH meter readings and to the literature values of plC,, (obtained in H20) for various substances, assuming their dissociation behavior in D20 to be similar to that of acetic acid, so that we could facilitate the identification process. Thus, the pK,, values reported below and in the Tables were all adjusted to represent pK,, values in D20.
Descriptive statistics as well as one-or two-tailed t-tests and a nonparametric test (Mann-Whitney Utest) were analyzed on a Macintosh Classic microcomputer using the program Statview (BrainPower, C alabasas, CA) (25) . Fig. 2 shows the 1-D 'H NMR spectrum of urine from a healthy man before and after ingesting betaine, 3 g twice daily for 7 days. Only the spectral region between 2.0 and 4.5 ppm is shown, as the higher and lower frequency regions had few resonances of direct interest.
Results
Identification Procedures
1-D NMR.
The postbetaine sample had a large betaine methyl singlet at 3.26 ppm (peak 8) and a significant concentration of DMG, as indicated by the singlet at 2.91 ppm (peak 13), pH 6.16. The peak areas indicated that the DMG concentration was -5% of that of betaine in this sample.
The concentration of DMG in other control and patients' samples was much lower, Urine from the other four subjects gave NMR spectra that indicated the presence of significant concentrations of betaine.
2-D NMR. 2-D COSYLR absolute-mode spectra ( Fig.  3) were obtained for the three patients' samples with an apparently high betaine:creatinine ratio; these spectra verified the identity of the main resonance assigned to betaine. The samples all had a cross-peak at 3.26 ppm/3.90 ppm, which are the chemical shifts of the trimethyland the methylene resonances, respectively, of betaine. Moreover, a cross-peak of high intensity also appeared in a spectrum of urine from the control subject who had ingested betaine. The cross-peak suggested a weak four-bond coupling from the N-methyl groups to the methylene protons of betaine. The 1-D spectra showed apparent singlets at the chemical shifts of betaine. The concentration of DMG was too low to give an unambiguous cross-peak in the spectra under the conditions we used. The homonuclear HartmannHahn (2-D NMR) spectra of the same samples did not Peak assignments: 8, betaine; 11,creatinine; 13, DMG (see Table 1 for assignments of the other peaks). DSS was used as the chemical shift reference (assigned to 0.000 ppm), and the pH was 6.02. These spectra were acquired at 400 MHz. in each fid; zero-filled once, sine-window apodization; magnitude mode.
As the COSYLR experiment was easier to set up and provided quicker data acquisition and processing, the Hartmann-Hahn approach was not used further.
pK,, measurements. The pD of urine from a patient who had been identified as having a high urinary betame concentration was adjusted and 'H NMR spectra were obtained at 20 different pH values. The peak that had been assigned to betaine remained at the same chemical shift independent of the variation in pH down to -3.5. At lower pH values a shift to higher frequency occurred. This is consistent with the known plC,, of betaine,which is 1.83 at 0#{176}C (15). The difference between pKa at 0#{176}C and 25#{176}C is -+0.02 pKa units, suggesting a plC, of betaine in H20 of -1.81 at 25#{176}C (26). The pK, (in D20) of the group giving peak 8 was 2.36 (see Table 1 ); this corresponds to a pK, of 1.84 in H20 after correction as described in Materials and Methods. Similarly, the pK, values for some of the remaining resonances agreed reasonably well with available literature values for glycine, creatinine, and creatine in D20 (see Table 1 ) (26). Excellent separation of betaine and other peaks in thb N-methyl characteristic region of the spectrum was obtained by using a pH5 of --5.
Standardization and Error Analysis
The linearity of the method was determined by analyzing control urine samples (n = 45) with eight different amounts of added betaine (Fig. 4) ; linear regression analysis of the data gave a slope of 1.05 ± 0.01 (r = 0.997, P = 0.0001), and the 95% confidence range for the slope was 1.02-1.07. The CVs of the betaine determinations at different concentrations ranged from -7% (n = 10) at low betaine concentrations to -1% (n = 9) at the highest concentration. These CV values correspond to absolute (SD) errors in the betaine concentration of 3-11 unoI/L. Some of the resonances near the betaine peak shifted with changes in pH*, giving an additional sample-dependent source of error. Thus, the most suitable pH5 range to be used in subsequent work was -5-5.5.
In addition, the spectral integration errors at different concentrations of betaine and creatinine in samples with a different background were determined by reintegration (n = 6) of NMR spectra from patients' samples containing high or low betaine concentrations, as well as controls (2 X 2 samples). The absolute errors increased with the concentration.
SDs were between 5 moI/L (at a low betaine concentration of 20 tmol/L) and 14 moIJL (at 600 mo1JL); for creatinine they were between 65 moIfL (at 4.5 mmol/L) and 225 moI/L (at 15 mmolfL).
Thus, the detection limit of betaine was -15 mol/L under optimal conditions, with little spectral overlap present. This could readily be achieved in most samples after adjustment to a suitable pH
w Betaine added (mmoI IL) However, the lower detection limit was strongly dependent on the degree of baseline correction required in the spectra.
Quantification and Normalization
The integrals of the combined creatinine and creatme resonance at 3.05 ppm, betaine at 3.26 ppm, and DSS at 0.000 ppm were determined.
Similarly, the DMG and glycine integrals were determined from the resolution-enhanced spectra. The absolute concentrations in the original fresh urine samples were then calculated by using the added DSS as a concentration calibrator.
In addition, the data from each patient and control sample were also normalized to the concentration of creatinine (e.g., ref. 27). A descriptive statistical summary of all the available NMR-derived concentration data is given in Table 2 .
The correlation between the absolute concentration values (mmoIIL) and the relative concentrations (mol%, mol/mol creatinine x 100) were determined by regression analysis.
The correlation coefficients for the control values were 0.96 for betaine (n = 17; P = 0.0001) and 0.94 for DMG (n = 8; P = 0.0005). The corresponding correlation coefficients for all values (patients and controls) were 0.85 for betaine (n = 30;P = 0.0001) and 0.83 for DMG (n = 19; P = 0.0001). Thus, the absolute and the relative concentration scales were equally useful, but the advantage of the latter was the presence of an internal concentration standard.
Patients vs Controls Figure 5 shows a comparison of the concentrations of urinary creatinine, betaine, DMG, and glycine in the samples from the controls, the patients, and the control subject who had ingested betaine over 7 days. The ordinate scale in this diagram is logarithmic to facilitate the more direct comparison of the different metabolite concentrations.
The average concentrations in the patients' urine samples were typically larger than those for the normal controls. However, the urinary betaine and DMG values were much smaller than those of the sample obtained from the control subject who had ingested betaine.
The mean, median, and errors of the creatinine, betame, DMG, and glycine data are also shown in Table   2 , presented separately for controls and patients. Analysis of the percentiles of the data showed that the patients' concentration distributions were broader and had a higher average than those describing the controls (although the calculated skewness values were approximately the same).
By a one-tailed Student's t-test, the creatinine (P = 0.08) and betaine concentrations (P = 0.09) and the betaine:creatinine ratio (P = 0.08) were not significantly higher (at the 95% level) in patients than in controls.
In contrast, the DMG (P = 0.01) and the DMG:creatinine ratio (P = 0.01) were significantly higher in the patients. Because of the skewness in the concentration distributions, we also used the nonparametric Mann-Whitney U-test (25) to test the significance of the results. This test showed that creatinine (P = 0.29) and glycine (P = 0.07) concentrations and the betaine:creatinine ratio (P = 0.15) were not significantly higher in the patients than in the controls. In contrast, the betaine (P = 0.05) and the DMG concentrations (P = 0.01) and the DMG:creatinine ratio (P = 0.01) were all significantly higher at the 95% confidence level. Therefore, the DMG concentration in the
patients was significantly and substantially higher than in the control subjects; the betaine concentration was marginally higher; and the concentrations of creatiine and glycine were not different between patients and controls.
Betaine-Creatinine Correlation
Preliminary results suggested a linear relation between urinary creatimne and betaine in the control subjects C1-C9. Although control subjects C10-C16 were active young men, we found that results from these seven additional controls did not extend the range of creatiine and betaine concentration values already recorded for control samples. However, these additional data points strengthened the linear relation, as shown in Fig. 6 . A linear regression line for the control samples (excluding the outlier control data point that appears at -21 mmol/L) is also shown. The slope of the line was (9.9 ± 3.0) X i0 mmoIJL betaine per 1 mmol/L creatiine (P = 0.01, r = 0.67, n = 16) and the intercept was 8.09 X i0 mmol/L betaine (the range for the slope estimate was 0.4-1.6 mol% at the 95% confidence level).
Discussion
Betaine Analysis
Assignments.
Betaine was identified
by 'H NMR in 1-D spectra of reconstituted urine samples. The peak assignment was made on the basis of its chemical shift relative to DSS in comparison with literature values (Table 1) , and confirmed by adding a small amount of authentic betaine to the samples, followed by simple acquisition of 1-D spectra. COSYLR spectra (optimized for long-range couplings) and 1-D spectra, coupled with pH titration, were also used. The main reason for using phase-sensitive spectral methods is generally that the resolution in the spectrum is enhanced, but for the detection of betaine we found that this was not suitable (see Fig. 3 ). The pH of the sample is one factor that is important for the accuracy of the betaine determinations. Peak 7 (in Fig. 2 ) is normally much larger than the betaine trimethyl resonance (peak 8 in Fig. 2 ). N-Methyls. Betaine N-methyl protons resonate in a section of the 'H NMR spectrum that contains peaks from several different N-methylated molecules, including carnitine and choline (see Fig. 2 and Table 1) (9). Ergothioneine, which has a betaine-like structure, has also been reported to be present in urine (29). However, the difference in chemical shift between the Nmethyl resonances of ergothioneine and betaine was readily detectable (data not shown). Because of this difference, and because of the low natural concentration of urinary ergothioneine [-5-40 tmoI/L (29)], the compound is unlikely to interfere directly with the determination of betaine in human urine. However, in patients who are under various pharmacological regimens related to their vascular conditions, the drugs can contribute spectral peaks in 'H NMR spectra of their urine samples.
0MG Analysis
The only --10% of that of betaine in the control subjects' samples. In addition, the sensitivity to detection of the DMG resonance is lower than that of betaine because of the fewer protons contributing to it. However, the signal-to-noise ratio was not a major problem, as can be seen from the very low noise level in the 1-D spectra.
Betaine and 0MG in Human Urine
Urinary betaine. Betaine has been found in high concentration in the urine of human neonates (27, 30) and young rats (9, 27, 31, 32) ; there are few reports of betaine in the urine of normal human adults and adult rats. The betaine:creatiine concentration ratio in urine typically peaks --6 days after birth, and can reach 75 mol% in some cases (33) . The ratios found for the controls in the present study were far lower, of the order of only 1 mol%. The betaine:creatinine concentration ratio in some of the patients' samples reached 4-6 mol%, which was higher than in most of the controls, although still substantially lower than that for human neonates. However, the betaine:creatinine concentration ratio (74 mol%) reached neonatal values in a sample from the control subject who had ingested betame.
Creatinine
normalization.
Because the amount of urinary creatimne excreted per day is related to the muscle volume of the subject and because of the renal clearance features of creatinine, this compound has often been used as an internal standard to normalize urinary metabolite concentrations.
To assess the validity of using creatinine-normalized betaine concentration data, we obtained samples from control subjects who were expected to have a "representative" distribution of urinary creatinine concentrations.
The plot of the concentration of urinary betaine vs creatinine (Fig.  6) for the controls was linear except for one control subject who had abnormally high urinary betaine and abnormally low urinary DMG concentrations (data not shown). Because this control subject appeared to have had previously undetected low activity of BHMT, his betaine:creatinine concentration was excluded from control values. Apart from this one control subject, there appeared to be a significant correlation between betaine and creatinine concentration, and the use of normalized data therefore was warranted. The apparent linear correlation between urinary concentrations of creatinine and betaine has not been reported previously. This correlation could reflect the similarities in structure between the two compounds, and raises the possibility that both compounds are secreted into the urine by like mechanisms.
High betaine concentrations.
Whereas most of our patients and control subjects had urinary betaine:creatinine concentration ratios within 1 SD of the normal mean, three patients and one control subject had higher values. This could have resulted from either increased circulating betaine, decreased creatinine, or changes in renal function.
Since routinely measured renal functions of the three patients were normal (the renal function of the control was not tested), we favored the first possibility for the three patients.
Metabolic implications.
Increased circulating betaine concentrations may be caused by either recently ingested betaine, enhanced biosynthesis of betaine from choline, or impaired catabolism by the following pathway (32, 34) , each step of which is enzyme-catalyzed:
BHMT choline -'betaine aldehyde-+betaine -
DMG-'
sarcosine-'glycine -'serine Changed activities of any one of the enzymes involved could conceivably affect circulating and urinary betaine concentrations.
We postulated that the homocyst(e)inemia and high urinary betaine in the three patients could be evidence of impaired BHMT activity (Fig. 1) , which would be supported by a finding of decreased urinary DMG. However, the ratios of DMG: creatinine concentration in the urine from these patients, at 5.7, 6.0, and 7.9 mol%, were all <2 SD above the normal mean of 1.5 ± 1.7 (SD) mol%. This finding suggested that increased concentrations of urinary DMG as found in these patients indicated enhanced, rather than depressed, BHMT activity.
These results showed that, in patients with hyperhomocysteinemia, urinary betaine concentrations were generally within the normal range. However, in cases in which betaine concentrations were significantly increased, DMG concentrations were commensurately high, apparently ruling out the possibility of impaired BHMT activity in these patients. In fact, concentrations of urinary DMG appeared to be inversely related to the adequacy of homocysteine catabolism by the transsulfuration and folate-dependent remethylation pathways (4) . Therefore, in investigations of possible aberrations in the metabolism of methionine and homocysteine involving prospective changes of BHMT activity, NMR studies of urinary betaine and DMG concentrations have been very valuable. These compounds are present in urine in detectable concentrations, enhanced by the nine equivalent protons of betaine and the six equivalent protons of DMG. The concentrations contrast with the lower values for urinary methionine of 3.7 moI/L and for homocyst(e)ine of 0.21 mo1/L (35) . Since methionine has only three equivalent methyl protons and homocysteine has no methyl groups, concentrations of methionine and homocysteine are too low for detection by routine NMR methods, because they would require impractically long spectral accumulation times.
In summary, we demonstrated that 1H NMR is valuable for determining the concentrations of betaine and DMG in urine. Data on the reliability of the particular measurements are reported here for the first time. Also, we recorded the initial observation of an apparent relation between urinary concentrations of betaine and creatinine.
Significant concentrations of betaine and DMG, and their ready NMR detectability due to multiple equivalent methyl protons, make these compounds valuable indicators of physiological variations of BHMT activity.
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